T1	Disease	65 91	anaplastic lymphoma kinase
T2	Chemical	62 122	an anaplastic lymphoma kinase inhibitor ( crizotinib ) based
T3	Pharmacodynamic_phenotype	148 164	response rate in
T4	Disease	188 219	small cell lung cancer patients
T5	Disease	226 239	tumors harbor
T6	Genomic_variation	245 269	4 / ALK translocations .
R1	influences	Arg1:T1	Arg2:T2
R2	influences	Arg1:T1	Arg2:T3
R3	treats	Arg1:T1	Arg2:T4
R4	treats	Arg1:T1	Arg2:T5
R5	isAssociatedWith	Arg1:T1	Arg2:T6
R6	decreases	Arg1:T2	Arg2:T1
R7	increases	Arg1:T2	Arg2:T3
R8	treats	Arg1:T2	Arg2:T4
R9	treats	Arg1:T2	Arg2:T5
R10	isAssociatedWith	Arg1:T2	Arg2:T6
R11	isAssociatedWith	Arg1:T3	Arg2:T1
R12	isAssociatedWith	Arg1:T3	Arg2:T2
R13	treats	Arg1:T3	Arg2:T4
R14	isAssociatedWith	Arg1:T3	Arg2:T5
R15	isAssociatedWith	Arg1:T3	Arg2:T6
R16	decreases	Arg1:T4	Arg2:T1
R17	isAssociatedWith	Arg1:T4	Arg2:T3
R18	isAssociatedWith	Arg1:T4	Arg2:T5
R19	isAssociatedWith	Arg1:T4	Arg2:T6
R20	isAssociatedWith	Arg1:T5	Arg2:T1
R21	influences	Arg1:T5	Arg2:T2
R22	isAssociatedWith	Arg1:T5	Arg2:T3
R23	isAssociatedWith	Arg1:T5	Arg2:T4
R24	isAssociatedWith	Arg1:T5	Arg2:T6
R25	influences	Arg1:T6	Arg2:T1
R26	influences	Arg1:T6	Arg2:T2
R27	influences	Arg1:T6	Arg2:T3
R28	isAssociatedWith	Arg1:T6	Arg2:T4
R29	isAssociatedWith	Arg1:T6	Arg2:T5
